Theravance Biopharma, Inc. (TBPH) Financials

TBPH Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 382.0 million 169.0 million
2023-09-30 413.6 million 167.5 million
2023-06-30 446.6 million 166.5 million
2023-03-31 538.6 million 168.0 million

TBPH Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -1.5 million 5.8 million
2023-09-30 -2.5 million 6.3 million
2023-06-30 -13.3 million 6.3 million
2023-03-31 -12.2 million 7.0 million

TBPH Net Income

No data available :(

TBPH Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 102.4 million - 49.2 million
2023-09-30 134.0 million - 41.1 million
2023-06-30 167.5 million - 42.5 million
2023-03-31 241.3 million - 43.8 million

TBPH Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 49.4 million
2023-09-30 52.4 million
2023-06-30 56.7 million
2023-03-31 62.9 million

TBPH Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 677000 8.3 million 15.8 million -
2023-09-30 21000 8.3 million 16.1 million -
2023-06-30 852000 9.4 million 19.3 million -
2023-03-31 938000 14.6 million 19.2 million -

TBPH Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 17.6 million 4.3 million
2023-09-30 15.7 million 1.3 million
2023-06-30 13.7 million 1.3 million
2023-03-31 10.4 million 1.7 million

TBPH

Price: $9.46

52 week price:
8.21
12.03

Earnings Per Share: -1.00 USD

P/E Ratio: -8.64

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 260600

Ebitda: -62.9 million

Market Capitalization: 450.8 million

Links: